Mental health AI
Therabot
Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist
Not assessed
Supervised research deployment; not available as an ordinary patient service.
This is not a zero score or an adverse agency finding.
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Research-stage, unclear in deployment
Legacy editorial placement, pre-method: 45
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 45
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 45. Not comparable with v1.3 positions.
Research-stage, unclear in deployment
Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.
Patient agency
How this tool changes agency
Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.
Public commercial availability and governance are not established by the bounded institutional-source pass
Patient agency assessment
Who sets and changes the goal?
Participants could initiate conversations inside a researcher-governed intervention. Enrollment restrictions are a research scope boundary, not evidence of coercion or diminished agency within participation.
What can the patient understand, question, or do?
Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.
Can the patient evaluate the conditions of use?
Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.
Text findings
Conditions of use
Published controls and their limits
Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.
What remains unknown?
Not tested or not established
Public commercial availability and governance are not established by the bounded institutional-source pass
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://home.dartmouth.edu/news/2025/03/first-therapy-chatbot-trial-yields-mental-health-benefits
- https://home.dartmouth.edu/news/2026/04/brian-pogue-and-nick-jacobson-receive-innovation-awards
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Public commercial availability and governance are not established by the bounded institutional-source pass No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Not assessed · Moderate for historical trial deployment, low for present commercialization (AI-assisted draft)